• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Iksuda, LegoChem Expand ADC Alliance contractpharma
    June 23, 2021
    Grants Iksuda access to LegoChem's next generation ADC platform for up to six targets.
  • Iksuda Therapeutics raises $47m to progress ADC pipeline pharmatimes
    June 08, 2021
    Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets.
  • Iksuda Therapeutics and Femtogenix Sign License Agreement pharmafocusasia
    March 07, 2019
    Iksuda Therapeutics (Iksuda), the next-generation Antibody Drug Conjugate (ADC) company, today announced it has signed a licensing agreement with Femtogenix Limited (FGX), the next-generation ADC payload company.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service